HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenblatt, A. Articles by Ross, C. A. Search for Related Content PubMed PubMed Citation Articles by Rosenblatt, A. Articles by Ross, C. A. Related Collections Huntington's disease Prognosis Trinucleotide repeat diseases

The association of CAG repeat length with clinical progression in Huntington disease

From the Department of Psychiatry (A.R., M.H.A.,L.M.G., R.L.M., J.B., C.A.R.), Johns Hopkins University School of Medicine, and Department of Biostatistics (K.-Y.L., H.Z.), School of Public Health, Johns Hopkins University, Baltimore, MD.

Address correspondence and reprint requests to Dr. A. Rosenblatt, Johns Hopkins Hospital, Meyer 2-181, 600 N. Wolfe St., Baltimore, MD 21287-7281; e-mail: arosenba{at}jhmi.edu

Objective: To determine whether the rate of clinical progression in Huntington disease (HD) is influenced by the size of the CAG expansion.

Methods: The dataset consisted of 3,402 examinations of 512 subjects seen through the Baltimore Huntington's Disease Center. Subjects were seen for a mean of 6.64 visits, with mean follow-up of 6.74 years. Subjects were administered the Quantified Neurological Examination, with its subsets the Motor Impairment and Chorea Scores, the Mini-Mental State Examination, and the HD Activities of Daily Living (ADL) Scale.

Results: In an analysis based on the Random Effects Model, CAG length was significantly associated with the rate of progression of all measures except chorea and ADL. There was a significant interaction term between CAG length and disease duration for all measures except chorea. Further graphical exploration of the data supported these linear models and suggested that subjects at the low end of the expanded CAG repeat range may experience a more benign late course.

Conclusions: CAG repeat length has a small effect on rate of progression that may be clinically important over time. Individuals with the shortest expansions appear to have the best prognosis. These effects of the CAG length may be relevant in the analysis of clinical trials.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 11 issue to find the title link for this article.

Supported by the National Institute of Neurological Disorders and Stroke and the Huntington's Disease Society of America.

Disclosure: Dr. Rosenblatt has given expert testimony related to the subject of this article.

Received June 3, 2005. Accepted in final form December 16, 2005.

This article has been cited by other articles:

				H H Ruocco, L Bonilha, L M Li, I Lopes-Cendes, and F Cendes Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat J. Neurol. Neurosurg. Psychiatry, February 1, 2008; 79(2): 130 - 135. [Abstract] [Full Text] [PDF]

				Does CAG Repeat Length Affect Clinical Progression in Huntington Disease? Journal Watch Neurology, June 8, 2006; 2006(608): 9 - 9. [Full Text]